IL-6

There are 5,039 papers on IL-6 in aging research: 753 trials and 1,580 observational studies in people, 1,417 in animals, 496 in cells, 720 reviews. The newest story, Nov 17, 2026: “Alzheimer's model mice fare worse in strength tests at middle age”.

Biomarker

5,039 papers study it1,600 findings

HGNCMGINCBI GeneTaxonMeSH

225 new papers in 30 daysSee all 5,039 papers on IL-6

At a glance

Human observational studies link higher IL-6 with older age and higher cardiovascular event risk, and associate IL-6 with frailty in people with multiple sclerosis. Human trials report decreases with several exercise and dietary interventions, but an hour of aerobic exercise increases IL-6 in untrained people with type 2 diabetes; a nicotinamide riboside trial shows no clear effect.

1,600 findings in 1,306 papers from 1993 to 2026, 183 of them since April 2026

“Higher IL6 levels were associated with a decreased likelihood of being a "good responder" (OR = 0.22, p = 0.018, 95% CI 0.06; 0.78)”
Association between inflammatory biomarkers and the cognitive response to a multidomain intervention: secondary longitudinal analyses from the MAPT studyGeroScience2025doi:10.1007/s11357-024-01497-2
  • Human trial753
  • Humans1,580
  • Animals1,404
  • Model organisms13
  • Cells496
  • In silico24

Interventions

234

Exercise

downin humans14upin humans4no changein humans2upin reviews2+2

22 studies
  1. Exercise decreases IL-6 in humans (SMD = -0.31).

    “Multilevel meta-analysis showed that exercise intervention could significantly reduce the levels of IL-6 (SMD = -0.31), CRP (SMD = -0.44), and TNF-α (SMD = -0.40) in the elderly.”

    Human trialserumn = 6,493

    Comparative efficacy of aerobic training, resistance training, combined training, and multicomponent exercise on interleukin-6, C-reactive protein, and tumor necrosis factor-α levels in older adults (≥60 years): a systematic review and network meta-analysis

    Frontiers in physiology

  2. Exercise increases IL-6 in FM patients (mean delta: +0.37 ± 0.14 pg/mL).

    “IL-6 increased significantly in the FM group (0.41 ± 0.07 vs. 0.79 ± 0.14 pg/mL; p=0.013; r=0.64; mean delta: +0.37 ± 0.14 pg/mL).”

    Human trialin FM patients16 weeksn = 15

    Divergent intestinal barrier and neuroimmune responses to supervised exercise across fibromyalgia, irritable bowel syndrome, and their comorbidity phenotypes: a prospective interventional study

    Frontiers in physiology

  3. Exercise increases IL-6 in FM patients (mean delta: +0.37 pg/mL, p=0.013).

    “In the FM group, IL-6 increased (mean delta: +0.37 pg/mL, p=0.013) and GPCS improved (p=0.047).”

    Human trialin FM patients16 weeks

    Divergent intestinal barrier and neuroimmune responses to supervised exercise across fibromyalgia, irritable bowel syndrome, and their comorbidity phenotypes: a prospective interventional study

    Frontiers in physiology

  4. Exercise showed no clear effect on IL-6 in older adults with frailty and/or sarcopenia (SMD -0.04 (95% CI -0.17 to 0.09)).

    “exercise interventions did not significantly improve serum interleukin-6 (IL-6) (SMD = -0.04, 95% CI: -0.17 to 0.09, p = 0.52, I2 = 10%)”

    Human trialin older adults with frailty and/or sarcopenia

    Effects of exercise interventions on inflammatory biomarker levels in older adults with frailty and/or sarcopenia: a systematic review and meta-analysis

    Frontiers in immunology

  5. Exercise showed no clear effect on IL-6 in humans (overweight and obese postmenopausal women).

    “Changes in IL-6 and adiponectin were not statistically significant.”

    Human trialoverweight and obese postmenopausal womenfemalesn = 2,124

    Effects of exercise intensity and volume on systemic inflammation in overweight and obese postmenopausal women: a dose-response meta-analysis

    Frontiers in immunology

  6. Exercise decreases IL-6 in older adults with 1 chronic disease.

    “Repeated measures ANOVA demonstrated significant decrease in both IL-6 and cortisol for CD1 (p’s <.01) following the intervention, but not for CD0 and CD2.”

    Human trialin older adults with 1 chronic disease6 monthsn = 43

    Effects of Exercise on Inflammation and Stress in Older Adults with Varying Chronic Disease Burden

    GSA 2025 abstract

  7. Exercise increases IL-6 in humans (moderate exercise).

    “Additionally, only female participants exhibited an increase in circulating IL-6 levels post-exercise indicating a sex-specific inflammatory response to moderate exercise.”

    Human trialmoderate exercise30 minutes

    Acute exercise alters immune responses in older adults, with extracellular vesicle changes observed in a high-intensity intervention

    Frontiers in immunology

  8. Exercise decreases IL-6 in humans (patients with obesity and well-controlled asthma, at peak exercise).

    “At peak exercise, both the O-A and NW-A groups showed reductions in plasma concentrations of IL-5, IL-6, and leptin.”

    Human trialpatients with obesity and well-controlled asthma, at peak exercisen = 12

    A short bout of exercise impacts TH2 inflammation of patients with obesity and well-controlled asthma

    Annals of thoracic medicine

  9. Exercise decreases IL-6 in humans.

    “After physical activity, the plasmatic concentration of IL‐6 and the IL‐6/IL‐10 ratio was reduced in frail subjects specifically (p < 0.05), which was paralleled by a slight increase in TNF‐a (p < 0.05).”

    Human trial12 weeks

    Effects of the VIVIFRAIL Exercise Protocol on Circulatory and Intracellular Peripheral Mediators Bridging Mitochondrial Dynamics and Inflammation in Robust and Frail Older People

    Aging cell

  10. Exercise increases IL-6 in humans (moderate continuous exercise (60% VO 2max for 30 minutes)).

    “Interestingly, IL-6 levels increased 30 min moderate exercise exclusively in females.”

    Human trialmoderate continuous exercise (60% VO 2max for 30 minutes)30 minutesfemalesn = 14

    Exercise intensity shapes acute and prolonged immune and extracellular vesicle responses in older adults

    medRxivPreprint

All 25

More on Exercise

Resistance training

downin humans9no changein humans3upin humans1−50% to −21%

13 studies
  1. Resistance training decreases IL-6 in humans.

    “The intervention also reduced plasma IL-6 concentrations and markedly increased circulating IL-10 and Klotho levels, indicating a favorable anti-inflammatory and anti-aging response.”

    Human trialsupervised programplasmathree sessions/week12 weeksn = 60

    Resistance training strengthened breathing muscles in older adults

    Journal of functional morphology and kinesiology

  2. Resistance training decreases IL-6 in humans.

    “After the 4‐week resistance‐training exposure, the biomarker profile shifted toward lower circulating inflammatory tone and higher peripheral neurotrophic signaling, with interleukin‐6 and tumor necrosis factor‐alpha decreasing while BDNF increased.”

    Human trial4 weeksn = 500

    An Exploratory Study of the Short-Term Association of Resistance Training With Circulating Inflammatory Biomarkers, Plasma Brain-Derived Neurotrophic Factor, and Cognitive Function in Healthy Midlife Adults

    Brain and behavior

  3. Resistance training decreases IL-6 in humans (-0.74 pg/mL).

    “The corresponding mean changes were -0.74 pg/mL for IL-6, -0.49 pg/mL for TNF-α, and +2.7 ng/mL for BDNF, with all paired comparisons statistically significant.”

    Human trialplasma4 weeksn = 500

    An Exploratory Study of the Short-Term Association of Resistance Training With Circulating Inflammatory Biomarkers, Plasma Brain-Derived Neurotrophic Factor, and Cognitive Function in Healthy Midlife Adults

    Brain and behavior

  4. Resistance training decreases IL-6 in patients with T2DM.

    “resistance training (RT) was associated with statistically credible reductions in both TNF-α and IL-6”

    Human trialin patients with T2DM

    Comparative Effects of Different Exercise Modalities on Circulating Adipokines and Inflammatory Cytokines in Adults With Type 2 Diabetes: A Network Meta-Analysis

    Diabetes, obesity & metabolism

  5. Resistance training decreases IL-6 in RE and RE + EAA groups.

    “IL-6 and IL-1β were significantly reduced in the RE (p < 0.05) and RE + EAA (p < 0.05) groups”

    Human trialin RE and RE + EAA groups12 weeksfemales

    Combined resistance exercise and essential amino acid intake enhance follistatin/myostatin ratio and muscle fitness in older women: a randomized controlled trial

    Journal of the International Society of Sports Nutrition

  6. Resistance training decreases IL-6 in humans (p<0.0001).

    “resistance training decreased serum levels of pro-inflammatory cytokines, interleukin-6 (p<0.0001)”

    Human trialplasma-serum12 weeksn = 31

    Resistance Training Improves Hemodynamics Involving Autonomic and Immune Responses

    International journal of sports medicine

  7. Resistance training increases IL-6 in humans (combined with n-3 supplementation (n-3+RT group)).

    “IL-6 increased in the n-3+RT group.”

    Human trialcombined with n-3 supplementation (n-3+RT group)16 weeksfemales

    Myokine Circulating Levels in Postmenopausal Women with Overweight or Obesity: Effects of Resistance Training and/or DHA-Rich n-3 PUFA Supplementation

    Nutrients

  8. Resistance training showed no clear effect on IL-6 in humans.

    “but no effect on interleukin-6, tumor necrosis factor-alpha, and myostatin”

    Human trial

    Effectiveness of resistance training on body composition, muscle strength, and biomarker in sarcopenic older adults: A meta-analysis of randomized controlled trials

    Archives of gerontology and geriatrics

  9. Resistance training showed no clear effect on IL-6 in humans.

    “Between exercise and control group effects and group x cognitive status interaction effects derived from the ANCOVA test were nonsignificant for IGF-1, IL-6, and KYN.”

    Human trial12 weeksn = 70

    Resistance training's impact on blood biomarkers and cognitive function in older adults with low and high risk of mild cognitive impairment: a randomized controlled trial

    European review of aging and physical activity : official journal of the European Group for Research into Elderly and Physical Activity

  10. Resistance training decreases IL-6 in humans.

    “The ANOVA for group×time only showed a significant effect on IL-6 (IL-6: F(3,86) = 3.66, p = 0.01; ηp2 = 0.11).”

    Human trial32 weeksfemalesn = 109

    Long-Term Effects of Microfiltered Seawater and Resistance Training with Elastic Bands on Hepatic Parameters, Inflammation, Oxidative Stress, and Blood Pressure of Older Women: A 32-Week, Double-Blinded, Randomized, Placebo-Controlled Trial

    Healthcare (Basel, Switzerland)

All 15

More on Resistance training

Aerobic exercise

downin humans5no changein humans1upin humans1

7 studies
  1. Aerobic exercise decreases IL-6 in humans (Adjusted between-group difference −15.58 pg/mL, 95% CI −20.72 to −10.45; FDR < 0.001).

    “only IL-6 retained statistical significance after BH-FDR correction (adjusted between-group difference: −15.58 pg/mL, 95% CI: −20.72 to −10.45; FDR < 0.001).”

    Human trialBreast cancer during anthracycline-based chemotherapy; baseline-adjusted sensitivity analysis12 weeksn = 40

    Exploratory Plasma Metabolomic Analysis of Aerobic Exercise-Associated Responses During Anthracycline-Based Chemotherapy in Patients with Breast Cancer: A Randomized Controlled Trial

    Metabolites

  2. Aerobic exercise decreases IL-6 in humans.

    “After adjustment for baseline values using ANCOVA, significant between-group differences were observed for all circulating biomarkers, consistently favoring the exercise group.”

    Human trial12-weeksn = 26

    Biomarkers and arterial stiffness. A sub-analysis of the "Exercise training in heart failure with reduced ejection fraction and permanent atrial fibrillation: A randomized clinical trial"

    Clinics (Sao Paulo, Brazil)

  3. Aerobic exercise showed no clear effect on IL-6 in humans.

    “Regarding molecular outcomes, neither intervention affected IL-6 concentrations.”

    Human trialserum16-weekfemales

    Effects of 16-week aerobic exercise and whole-body vibration on myokines and neurocognitive indices in postmenopausal women: A randomized control study

    Archives of gerontology and geriatrics

  4. Aerobic exercise decreases IL-6 in humans with dietary calorie restriction in knee osteoarthritis (1.36 mg/dL vs 2.98 mg/dL, d = 1.69).

    “IL-6 was lower (p < 0.01; d = 1.69) at post-intervention in the CR + E group (1.36 mg/dL, 0.72 to 2.00) compared to CR group”

    Human trialwith dietary calorie restriction in knee osteoarthritis4 weeksn = 23

    The effects of short-term dietary calorie restriction combined with aerobic exercise on systemic inflammation in overweight or obese individuals with knee osteoarthritis: a randomised controlled trial

    Musculoskeletal science & practice

  5. Aerobic exercise increases IL-6 in humans (type 2 diabetes, untrained) (+26% (p=0.02)).

    “Circulating IL-6 levels increased 26% (p=0.02) following exercise.”

    Human trialtype 2 diabetes, untrainedtreadmill walking at 65-70% of predetermined VO2 maxblood60 minutesn = 12

    Extracellular Vesicle and Immune Cell Responses to Aerobic Exercise Are Blunted in Type 2 Diabetes

    ADA Scientific Sessions 2025 abstract

  6. Aerobic exercise decreases IL-6 in humans (People with overweight or obesity; versus control) (Hedges g 0.70 (95% CI 0.32 to 1.07); positive values indicate greater IL-6 reduction).

    “AE versus control was 0.70 (0.32 to 1.07)”

    ReviewPeople with overweight or obesity; versus control

    Comparative Effects and Dose–Response Relationships of Exercise Modalities on Resting Circulating Interleukin-6 in People with Overweight or Obesity: A Systematic Review and Dose–Response Network Meta-Analysis

    Metabolites

  7. Aerobic exercise decreases IL-6 in humans (added to energy restriction vs energy restriction alone) (SMD -0.35, 95% CI -0.64 to -0.06).

    “and IL-6 (SMD -0.35, 95% CI -0.64 to -0.06)”

    Reviewadded to energy restriction vs energy restriction alone

    Comparative efficacy of exercise modalities added to energy restriction on inflammatory markers in obesity: a systematic review and network meta-analysis

    Frontiers in nutrition

More on Aerobic exercise

Resveratrol

downin human cells2no changein humans2upin mice2downin rats1

7 studies
  1. Resveratrol decreases IL-6 in rats (spinal cord injury; treatment beginning 14 days post-injury).

    “Resveratrol supplementation, alone and combined with exercise, significantly reduced spinal cord IL-6 relative to control, whereas exercise alone did not.”

    Animalsspinal cord injury; treatment beginning 14 days post-injuryspinal cord10 mg/kg daily4 weeksmales

    Effect of Aerobic Training Combined with Resveratrol on Spinal Cord IL-6, TNF-α, and Locomotor Recovery after Spinal Cord Injury in Rats

    Research SquarePreprint

  2. Resveratrol showed no clear effect on IL-6 in humans (type 2 diabetes mellitus) (SMD -1.35, 95% CI -2.75 to -0.05).

    “no significant difference was observed in improving interleukin-6 levels (SMD = -1.35, 95%CI(-2.75, -0.05), P = 0.06; Level of evidence: very low), tumor necrosis factor α levels”

    Reviewtype 2 diabetes mellitusn = 533

    The efficacy of resveratrol supplementation on inflammation and oxidative stress in type-2 diabetes mellitus patients: randomized double-blind placebo meta-analysis

    Frontiers in endocrinology

  3. Resveratrol decreases IL-6 in human cells (Basal conditions and peroxide-induced oxidative environment).

    “A decrease in these two cytokines was also observed in cells treated with resveratrol, both at basal levels and in an oxidizing environment (with peroxide).”

    CellsBasal conditions and peroxide-induced oxidative environmentleukocyte5μm24 hours

    Silencing of the Nrf2 pathway in aging promotes a decrease in the anti-inflammatory effect of resveratrol

    Archives of gerontology and geriatrics

  4. Resveratrol showed no clear effect on IL-6 in humans (primary and secondary prevention) (P=0.58 (primary), P=0.57 (secondary)).

    “No significant difference was observed in interleukin-6 (IL-6) expression with P=0.58 for primary prevention and P=0.57 for secondary prevention.”

    Reviewprimary and secondary prevention

    Resveratrol as an Anti-inflammatory Agent in Coronary Artery Disease: A Systematic Review, Meta-Analysis and Meta-Regression

    Chinese journal of integrative medicine

  5. Resveratrol increases IL-6 in busulfan and cyclophosphamide-treated mice.

    “After resveratrol-βcd treatment, the levels of IL-6 in the ovaries were significantly increased, and the progression of POI was suppressed.”

    Animalsin busulfan and cyclophosphamide-treated miceovary

    Resveratrol-βcd inhibited premature ovarian insufficiency progression by regulating granulosa cell autophagy

    Journal of ovarian research

  6. Resveratrol increases IL-6 in Western diet-fed LDLr(-/-) mice.

    “led to an increase in IL-6”

    Animalsin Western diet-fed LDLr(-/-) miceliver0.60 mg/day

    Trans-resveratrol reduced hepatic oxidative stress in an animal model without inducing an upregulation of nuclear factor erythroid 2-related factor 2

    Journal of clinical biochemistry and nutrition

  7. Resveratrol decreases IL-6 in AGEs-stimulated human gingival fibroblasts.

    “the administration of resveratrol suppresses the generation of IL-6 and IL-8 and cell senescence via inhibiting NF-κB signaling pathway.”

    Cellsin AGEs-stimulated human gingival fibroblasts

    Resveratrol attenuates advanced glycation end product-induced senescence and inflammation in human gingival fibroblasts

    Journal of dental sciences

More on Resveratrol

Metformin

downin humans4downin human cells2

6 studies
  1. Metformin decreases IL-6 in humans (Peri-implantitis; adjunctive to mechanical debridement versus mechanical debridement alone) (8.13 pg/mL vs. 19.23 pg/mL).

    “IL-6 levels (8.13 pg/mL vs. 19.23 pg/mL, P < 0.001) compared with the control.”

    Human trialPeri-implantitis; adjunctive to mechanical debridement versus mechanical debridement alonegelperi-implant crevicular fluid1%6 monthsn = 54

    Harnessing the Therapeutic Potential of Locally Delivered 1% Metformin Gel for Modulation of Clinical and Inflammatory Parameters in Peri-Implantitis Disease: A Prospective Clinical Evaluation

    Journal of long-term effects of medical implants

  2. Metformin is linked with lower IL-6 in humans (patients with newly diagnosed T2DM).

    “significant reductions in TNF-α, IL-6, glycated hemoglobin (HbA1c), and fasting plasma glucose levels were observed in both groups (p < 0.001)”

    Humanspatients with newly diagnosed T2DM6 months

    Effects of Metformin Monotherapy Versus Metformin Plus SGLT-2 Inhibitor Therapy on Molecular and Cellular Inflammatory Markers in Patients with Newly Diagnosed Type 2 Diabetes Mellitus

    Journal of clinical medicine

  3. Metformin is linked with lower IL-6 in humans (newly diagnosed type 2 diabetes) (p<0.05).

    “IL-6 levels decreased at each visit, with a statistically significant difference between the first and second follow-ups (p<0.05).”

    Humansnewly diagnosed type 2 diabetes

    Metformin modulates antioxidant and anti-inflammatory biomarkers in newly diagnosed patients with type 2 diabetes mellitus: an observational study

    Journal of basic and clinical physiology and pharmacology

  4. Metformin is linked with lower IL-6 in humans (COVID-19 with type 2 diabetes) (median 4.0 pg/ml vs 12.3 pg/ml, p = 0.026).

    “those receiving treatment had significantly lower levels of IL-6 (median, 12.3 pg/ml vs. 4.0 pg/ml, p = 0.026)”

    HumansCOVID-19 with type 2 diabetes

    Metformin alleviates inflammatory response and severity rate of COVID-19 infection in elderly individuals

    Scientific reports

  5. Metformin decreases IL-6 in PDGFβ-treated orbital fibroblasts from TED patients.

    “Metformin treatment restored AMPK phosphorylation, reduced HA accumulation (∼2.3-3.1-fold), and decreased IL-6 and IL-8 production.”

    Cellsin PDGFβ-treated orbital fibroblasts from TED patients

    Metformin inhibits PDGFβ signaling to suppress hyaluronan and cytokine production in thyroid eye disease

    Experimental eye research

  6. Metformin decreases IL-6 in lymphocytes.

    “metformin treatment restrained the production of the proinflammatory cytokine IL-6 in lymphocytes”

    Cellsin lymphocytes

    The effect of metformin on senescence of T lymphocytes

    Immunity & ageing : I & A

More on Metformin

Combined aerobic and resistance training

downin humans3no changein humans2

5 studies
  1. Combined aerobic and resistance training showed no clear effect on IL-6 in humans.

    “IL-6, CRP, TNF-α, fatigue, vigor and REE were unchanged.”

    Human trialsupervisedweeks 16 to 32femalesn = 57

    Frequency-dependent adaptations in energy expenditure, strength, mood, and inflammation following 16 to 32 weeks of combined aerobic and resistance training in older women

    European journal of applied physiology

  2. Combined aerobic and resistance training decreases IL-6 in humans (pooled across RCTs in postmenopausal women with overweight or obesity) (SMD = -1.58, 95% CrI [-2.62, -0.56]).

    “CT downregulated circulating interleukin-6 (IL-6) (SMD = -1.58, 95% CrI [-2.62, -0.56])”

    Reviewpooled across RCTs in postmenopausal women with overweight or obesityfemales

    Modality-specific effects of structured exercise on immunometabolic biomarkers in postmenopausal obesity: a Bayesian network meta-analysis

    Frontiers in immunology

  3. Combined aerobic and resistance training decreases IL-6 in humans (breast cancer survivors) (SUCRA: IL-6, 88.64; IL-8, 85.74; TNF-α, 88.56).

    “CE showed the highest probability of reducing IL-6 (SUCRA, 88.64), IL-8 (85.74), and TNF-α (88.56).”

    Reviewbreast cancer survivors

    Different exercise modalities and their effects on the inflammatory mediator repertoire in breast cancer survivors: A systematic review with Bayesian network meta-analysis and dose-response analysis

    European journal of oncology nursing : the official journal of European Oncology Nursing Society

  4. Combined aerobic and resistance training decreases IL-6 in type 2 diabetes mellitus patients with overweight or obesity (SMD = -0.93, 95% CI: -1.63, -0.23, P = 0.01).

    “CE appears to offer the greatest potential in lowering IL-6 (SUCRA=76.6; SMD=-0.93; 95% CI: -1.63, -0.23; P=0.01) levels.”

    Reviewin type 2 diabetes mellitus patients with overweight or obesity

    Comparative effects of different exercise types on inflammatory markers in type 2 diabetes mellitus patients with overweight and obesity: a systematic review and network meta-analysis

    BMC endocrine disorders

  5. Combined aerobic and resistance training showed no clear effect on IL-6 in humans (sarcopenic obesity) (p > 0.05).

    “However, no significant improvements (p > 0.05) were observed in IL-6, CRP, total cholesterol, triglycerides, trunk fat, BF mass, and MIHS.”

    Reviewsarcopenic obesityn = 453

    Effects of Concurrent Training on Biomarkers, Morphological Variables, and Physical Performance in People with Sarcopenic Obesity: A Meta-Analysis with Meta-Regression

    Medicina (Kaunas, Lithuania)

More on Combined aerobic and resistance training

Dasatinib + quercetin

upin humans3downin mice1

4 studies
  1. Dasatinib + quercetin increases IL-6 in humans.

    “Though these outcomes would not have survived corrections for multiple comparisons, there were significant post-treatment increases in the following multifunctional biofluid proteins: plasma fractalkine and MMP-7, and CSF IL-6; other analytes that displayed trends toward change at P < 0.1 were plasma eotaxin and VEGF ( and Supplementary Table 2”

    Human trialCSFthree monthsn = 5

    Evaluation of Exploratory Fluid Biomarker Results from a Phase 1 Senolytic Trial in Mild Alzheimer's Disease

    Research squarePreprint

  2. Dasatinib + quercetin increases IL-6 in humans (P = 0.008; t(4) = 3.913).

    “CSF levels of interleukin-6 (IL-6) and glial fibrillary acidic protein (GFAP) increased (t(4) = 3.913, P = 0.008 and t(4) = 3.354, P = 0.028, respectively)”

    Human trialcerebrospinal fluid12 weeksn = 5

    Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial

    Nature medicine

  3. Dasatinib + quercetin increases IL-6 in humans.

    “In CSF, thymus- and activation-regulated chemokine (TARC), IL-17A, I-TAC, eotaxin-2, eotaxin and MIP-1α levels decreased and IL-6 levels increased from baseline to post-treatment.”

    Human trialcerebrospinal fluid12 weeksn = 5

    Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial

    Nature medicine

  4. Dasatinib + quercetin increases IL-6 in humans (open-label 12-week pilot in early-stage Alzheimer's disease) (t(4)=3.913, p=008).

    “CNS levels of IL-6 and GFAP increased from baseline to post-treatment (t(4)=3.913, p=008 and t(4)=3.354, p=0.028, respectively)”

    Human trialopen-label 12-week pilot in early-stage Alzheimer's diseasecentral nervous system12 weeksn = 5

    Senolytic therapy to modulate the progression of Alzheimer's Disease (SToMP-AD) - Outcomes from the first clinical trial of senolytic therapy for Alzheimer's disease

    Research squarePreprint

  5. Dasatinib + quercetin increases IL-6 in humans.

    “In CSF, TARC, IL-17A, I-TAC, Eotaxin-2, Eotaxin, and MIP-1α levels decreased, and IL-6 levels increased from pre- to post-treatment (”

    Human trialcerebrospinal fluid12-weekn = 5

    Senolytic therapy to modulate the progression of Alzheimer's Disease (SToMP-AD) - Outcomes from the first clinical trial of senolytic therapy for Alzheimer's disease

    Research squarePreprint

  6. Dasatinib + quercetin decreases IL-6 in mice (physiological aging).

    “downregulated Il6, Mmp13 and Lamb1 expression”

    Animalsphysiological aging5 mg/kg and 50 mg/kg10 monthsmales

    Dasatinib and quercetin prevent alveolar bone loss in aged mice

    Journal of periodontology

More on Dasatinib + quercetin

SGLT2 inhibitors

downin humans3no changein humans1

4 studies
  1. SGLT2 inhibitors showed no clear effect on IL-6 in humans (MD -1.53 pg/mL; 95% CI -3.69 to 0.64; I2 = 89.8%).

    “or IL-6 (MD -1.53 pg/mL; 95% CI -3.69 to 0.64; I 2 = 89.8%)”

    Human trialperipheral blood

    Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Inflammatory Biomarkers: A Systematic Review and Meta-Analysis

    Diabetes, obesity & metabolism

  2. SGLT2 inhibitors are linked with lower IL-6 in humans (compared with non-SGLT2i users) (p<0.001).

    “with lower valvular NF-κB and IL-6 expression and reduced circulating IL-6 (p<0.001)”

    Humanscompared with non-SGLT2i usersplasma

    SGLT2 inhibitors and molecular signatures of aortic valve remodeling in severe aortic stenosis: the Valve-AS study

    ESC Congress 2026 abstract

  3. SGLT2 inhibitors are linked with lower IL-6 in humans (newly diagnosed T2DM, baseline-adjusted vs metformin monotherapy) (B = -37.87, β = -0.31, 95% CI -73.52 to -2.23).

    “treatment group was associated with a lower six-month IL-6 level (B = -37.87, β = -0.31, p = 0.038; 95% CI, -73.52 to -2.23)”

    Humansnewly diagnosed T2DM, baseline-adjusted vs metformin monotherapy6 months

    Effects of Metformin Monotherapy Versus Metformin Plus SGLT-2 Inhibitor Therapy on Molecular and Cellular Inflammatory Markers in Patients with Newly Diagnosed Type 2 Diabetes Mellitus

    Journal of clinical medicine

  4. SGLT2 inhibitors decrease IL-6 in humans (diabesity).

    “Both classes consistently lower levels of systemic cytokines such as IL-6 and hsCRP and improve endothelial function, collectively mitigating cardiometabolic risk.”

    Reviewdiabesity

    GLP-1 RAs vs. SGLT2is: Divergent pathways of cardiovascular inflammation control in obesity-associated diabetes

    Annales d'endocrinologie

More on SGLT2 inhibitors

Insulin

downin humans3

3 studies
  1. Insulin decreases IL-6 in humans (scheduled for elective orthopaedic surgery or pancreatic surgery with general anaesthesia) (P = 0.034, P = 0.044).

    “inhibited postoperative IL-6 and S100-β levels in Group I compared to Group S (P = 0.034, P = 0.044, respectively)”

    Human trialscheduled for elective orthopaedic surgery or pancreatic surgery with general anaesthesiaintranasal administrationserum40 IU/400 μLfrom 5 minutes before anaesthesia induction until 3 days postoperativelyn = 140

    Effect of intranasal insulin on perioperative cognitive function in older adults: a randomized, placebo-controlled, double-blind clinical trial

    Age and ageing

  2. Insulin decreases IL-6 in humans.

    “Besides, the serum levels of IL-6, TNF-α and S100β at T2−5 in the insulin group were significantly lower than those of the control group (IL-6: mean difference at T2, −4.14, p = 0.036; T3, −3.84, p = 0.039; T4, −3.37, p = 0.013; T5, −2.57, p = 0.042”

    Human trialintranasalserumstarting 2 days before surgery until 1 h before admission to the operating roomn = 61

    Efficacy and safety of intranasal insulin on postoperative cognitive dysfunction in elderly patients after laparoscopic radical resection of colorectal cancer: a double-blind pilot study

    Frontiers in aging neuroscience

  3. Insulin decreases IL-6 in humans after laparoscopic radical resection of colorectal cancer (mean difference at T2, -4.14).

    “The serum levels of IL-6, TNF-α and S100β at T2−5 in the insulin group were significantly lower than those of the control group”

    Human trialafter laparoscopic radical resection of colorectal cancerserumn = 61

    Efficacy and safety of intranasal insulin on postoperative cognitive dysfunction in elderly patients after laparoscopic radical resection of colorectal cancer: a double-blind pilot study

    Frontiers in aging neuroscience

  4. Insulin decreases IL-6 in humans (preoperative surgical patients) (MD -2.52; 95% CI -3.45 to -1.58).

    “Significant reductions in IL-6 (MD -2.52; 95% CI -3.45 to -1.58) and TNF-α (MD -5.02; 95% CI -8.67 to -1.36) were observed.”

    Reviewpreoperative surgical patients

    Effect of preoperative intranasal insulin on postoperative delirium in adult surgical patients: a systematic review, meta-analysis, and trial sequential analysis

    Perioperative medicine (London, England)

More on Insulin

GLP-1 receptor agonists

downin humans2no changein humans1

3 studies
  1. GLP-1 receptor agonists decrease IL-6 in humans (diabesity).

    “Both classes consistently lower levels of systemic cytokines such as IL-6 and hsCRP and improve endothelial function, collectively mitigating cardiometabolic risk.”

    Reviewdiabesity

    GLP-1 RAs vs. SGLT2is: Divergent pathways of cardiovascular inflammation control in obesity-associated diabetes

    Annales d'endocrinologie

  2. GLP-1 receptor agonists showed no clear effect on IL-6 in patients with type 2 diabetes mellitus (SMD = -0.52, 95% CI [-1.34 to 0.29], P = 0.21).

    “Although the results from 13 studies indicated a decreasing trend in IL-6 levels (SMD = -0.52), this change was not statistically significant (95% CI [-1.34 to 0.29], P = 0.21”

    Reviewin patients with type 2 diabetes mellitusn = 1,878

    The effects of GLP-1 receptor agonists on metabolic inflammatory markers in patients with type 2 diabetes mellitus: a systematic review and meta-analysis

    PeerJ

  3. GLP-1 receptor agonists decrease IL-6 in humans (type 2 diabetes; compared with insulin) (SMD -0.24, 95% CI -0.46 to -0.02).

    “GLP-1 RAs also significantly reduced IL-6 versus insulin (SMD = -0.24; 95% CI: -0.46 to -0.02).”

    Reviewtype 2 diabetes; compared with insulin

    Inflammatory biomarker response to GLP-1 receptor agonists versus other glucose-lowering medications in patients with type 2 diabetes: a systematic review and meta-analysis

    Frontiers in endocrinology

More on GLP-1 receptor agonists

Caloric restriction

no changein humans1downin humans1downin rats1

3 studies
  1. Caloric restriction showed no clear effect on IL-6 in humans (randomized to CR vs no CR).

    “there were no significant differences in IL-6, TNFr1, GDF15, or cystatin C by CR group”

    Human trialrandomized to CR vs no CR6 months

    Caloric Restriction and Changes in Geroscience Blood-Based Biomarkers in Older Adults

    GSA 2025 abstract

  2. Caloric restriction decreases IL-6 in humans (individuals with obesity/overweight) (SMD -0.31 pg/mL [95% CI -0.51 to -0.10]).

    “IL-6 with high heterogeneity (SMD -0.31 pg/mL [95% CI -0.51 to -0.10], p = 0.004”

    Reviewindividuals with obesity/overweight

    Effects of intermittent fasting and caloric restriction on inflammatory biomarkers in individuals with obesity/overweight: A systematic review and meta-analysis of randomized controlled trials

    Obesity reviews : an official journal of the International Association for the Study of Obesity

  3. Caloric restriction decreases IL-6 in LPS-treated rats.

    “partial reduction of serum interleukin-6, mediated by CR, attenuated the systemic response”

    Animalsin LPS-treated ratsserum4 or 8 weeks

    Calorie restriction protects against acute systemic LPS-induced inflammation

    Nutritional neuroscience

More on Caloric restriction

Nicotinamide riboside

no changein humans1downin mice1

2 studies
  1. Nicotinamide riboside showed no clear effect on IL-6 in humans.

    “We measured plasma levels of the SASP cytokine IL-6 and found higher levels in patients with COPD compared to lung-healthy controls, but no effects of NR treatment could be detected.”

    Human trial6 weeks

    Effect of nicotinamide riboside on airway inflammation in COPD: a randomized, placebo-controlled trial

    Nature aging

  2. Nicotinamide riboside decreases IL-6 in mice (heat-exposed mice).

    “NR also reduced the levels of IL-6, TNFα, TBARS, HIF-1α, and TRPM7”

    Animalsheat-exposed micekidney10 days before heat exposuremales

    Nicotinamide riboside protects mouse kidneys from heat injury through inhibition of inflammation, oxidative stress, and hypoxia response

    Archives of physiology and biochemistry

More on Nicotinamide riboside

Tirzepatide

downin humans2

2 studies
  1. Tirzepatide decreases IL-6 in humans (pooled comparison against placebo) (MD -17.8 (95% CI -24.3 to -11.3)).

    “and IL-6 (MD: -17.8; 95% CI: -24.3 to - 11.3; I2 = 1.6%)”

    Human trialpooled comparison against placebo

    Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis

    Reviews in endocrine & metabolic disorders

  2. Tirzepatide decreases IL-6 in humans (25–30% reduction).

    “and interleukin-6 by 25–30% at 72 weeks.”

    Review72 weeks

    Tirzepatide and inflammation: a critical reappraisal of the immunometabolic case for incretin-based therapy

    Reviews in endocrine & metabolic disorders

More on Tirzepatide

Aerobic training

downin humans1no changein rats1

2 studies
  1. Aerobic training decreases IL-6 in humans.

    “Aerobic training yielded optimal improvements in interleukin 6 and tumor necrosis factor alpha.”

    Human trialn = 3,516

    Exercise Effects on Inflammatory Markers in Middle-Aged and Older Adults: A Network Meta-Analysis

    Journal of the American Medical Directors Association

  2. Aerobic training showed no clear effect on IL-6 in rats (spinal cord injury; training beginning 14 days post-injury).

    “Resveratrol supplementation, alone and combined with exercise, significantly reduced spinal cord IL-6 relative to control, whereas exercise alone did not.”

    Animalsspinal cord injury; training beginning 14 days post-injurybody-weight-supported treadmill trainingspinal cord4 weeksmales

    Effect of Aerobic Training Combined with Resveratrol on Spinal Cord IL-6, TNF-α, and Locomotor Recovery after Spinal Cord Injury in Rats

    Research SquarePreprint

More on Aerobic training

Blood flow restriction training

upin humans1downin humans1

2 studies
  1. Blood flow restriction training increases IL-6 in humans Within-group change; greater increase than non-exercising control (+8.26 pg/mL from baseline).

    “IL-6 increased significantly following both BFRT (mean change = 8.26 pg/mL, p < 0.001) and EOE (mean change = 3.56 pg/mL, p = 0.013)”

    Human trialWithin-group change; greater increase than non-exercising controlSingle exercise boutmales

    Acute neurotrophic responses to a single bout of blood flow restriction and eccentric overload exercise in healthy older men

    GeroScience

  2. Blood flow restriction training decreases IL-6 in humans (70% AOP group compared with other groups) (-28.4% IL-6; -35.7% hs-CRP).

    “The 70% AOP group demonstrated the greatest reductions in inflammatory markers (IL-6: -28.4%; hs-CRP: -35.7%)”

    Human trial70% AOP group compared with other groups70% AOP12 weeksfemalesn = 180

    Personalized blood flow restriction training at variable occlusion pressures improves multisystem function in overweight and obese older women

    European journal of applied physiology

More on Blood flow restriction training

All 234

Effects

77

Cognitive function

mediatesin humans3downin humans2

5 studies
  1. IL-6 is linked with cognitive function in humans.

    “IL-6 emerged as a consistent significant mediator of the relationship between CRF and EF, episodic memory, visuospatial processing and working memory.”

    Humansparallel mediation models adjusted for age, sex, APOE4 carriage, body fat percentage, study site and years of education; association of CRF with EF, episodic memory, visuospatial processing and working memoryn = 648

    Inflammatory, metabolic, and vascular pathways linking cardiorespiratory fitness to cognition: Results from the IGNITE study

    Brain, behavior, & immunity - health

  2. IL-6 is linked with cognitive function in social isolation stress to cognitive function pathway.

    “the SIS-CF association diminished with the inclusion of IL6, highlighting its role as a putative mediator in this pathway.”

    Humansin social isolation stress to cognitive function pathwayn = 3,800

    ROLE OF INFLAMMATION AS SEX-SPECIFIC MEDIATOR BETWEEN CHRONIC STRESS AND COGNITIVE FUNCTION

    GSA 2024 abstract

  3. IL-6 is linked with worse cognitive function in humans (between-person: g = -.06, p =.04).

    “Higher stable differences and fluctuations over time in IL-6 were significantly associated with slower TMT-A performance for women and men”

    Humansn = 235

    GENDER-SPECIFIC EFFECTS OF IL-6 AND DECLINES IN PROCESSING SPEED AND EXECUTIVE FUNCTIONING IN OLDER ADULTS

    GSA 2024 abstract

  4. IL-6 is linked with worse cognitive function in humans (non-ε4 carriers) (β = -0.0257, SD = 0.0084, p = 0.0023).

    “those with the upper tertile of serum IL-6 levels experienced significantly accelerated CD (β = -0.0257 [SD = 0.0084, p = 0.0023]).”

    Humansnon-ε4 carriers6.4 yearsn = 1,120

    Prospective associations of interleukin-6 and APOE allele with cognitive decline in biracial community-dwelling older adults: The Chicago Health and Aging Project (CHAP)

    Alzheimer's & dementia (Amsterdam, Netherlands)

  5. IL-6 is linked with cognitive function in humans (between mushroom intake and Montreal Cognitive Assessment score) (12.76% mediation).

    “The association between mushroom intake and MCI was mediated by interleukin-6 (IL-6) and hypersensitive C-reactive protein (hs-CRP), and the MoCA score was 12.76% and 47.59%, respectively.”

    Humansbetween mushroom intake and Montreal Cognitive Assessment scoren = 248

    Investigating the association between inflammation mediated by mushroom consumption and mild cognitive impairment in Chinese older adults

    Food & function

Cellular senescence

upin cells2upin human cells2

4 studies
  1. IL-6 increases cellular senescence in cells (elevated in the uterine microenvironment).

    “elevated IL-6 in the uterine microenvironment exacerbates senescence”

    Cellselevated in the uterine microenvironmentuterus

    Uterine immune cells show aging signs in older pregnant women

    Aging cell

  2. IL-6 induces cellular senescence in cells (Intracellular IL-6 signaling).

    “This pathway triggered by intracellular IL-6 significantly contributes to cell-autonomous induction of senescence and impacts in tumor growth control.”

    CellsIntracellular IL-6 signaling

    The SASP factor IL-6 sustains cell-autonomous senescent cells via a cGAS-STING-NFκB intracrine senescent noncanonical pathway

    Aging cell

  3. IL-6 induces cellular senescence in neighboring uninfected cells.

    “HCMV-infected RPTECs have the ability to trigger a senescence/inflammatory loop in an IL-6-dependent manner, leading to the development of a similar senescence/inflammatory phenotype in neighboring uninfected cells”

    Cellsin neighboring uninfected cells

    Human cytomegalovirus infection triggers a paracrine senescence loop in renal epithelial cells

    Communications biology

  4. IL-6 induces cellular senescence in CS-AKI.

    “IL-6 activates the p53/ P21 pathway through GATA2/SERPINE1, which triggers senescence in CS-AKI and then promotes the progression of AKI”

    Cellsin CS-AKIkidney

    IL-6 mediated renal tubular cell senescence via GATA2/ SERPINE1 pathway

    Research SquarePreprint

More on Cellular senescence

Mortality

no changein humans2

2 studies
  1. IL-6 was not clearly linked with mortality in humans after correction for NT-proBNP; CHF patients with anemia (1.031 (0.931–1.143)).

    “but did not persist after correction for NT-proBNP [1.031 (0.931–1.143), p = 0.556]”

    Humansafter correction for NT-proBNP; CHF patients with anemiaup to 24 months

    Elevated Levels for Interleukin-6 as a Marker of Death Risk in Elderly and Senile Patients with CHF and Anemia: A Prospective Cohort Study

    Russian Journal of Geriatric Medicine

  2. IL-6 was not clearly linked with mortality in humans (heart failure inpatients).

    “sex, ECG major abnormality, BUN, and IL-6 were not.”

    Humansheart failure inpatientsn = 186

    Feasibility of multidomain cardiovascular-kidney-metabolic biomarker assessment for in-hospital mortality in older heart failure inpatients: an exploratory retrospective cohort study

    BMC geriatrics

Executive function

no changein humans1downin humans1

2 studies
  1. IL-6 was not clearly linked with executive function in humans (change in executive function, longitudinal latent change score models).

    “No similar effects were observed for IL6 or CRP.”

    Humanschange in executive function, longitudinal latent change score modelsmedian 17 yearsn = 599

    Executive function and soluble urokinase-type plasminogen activator receptor (suPAR): a longitudinal study of midlife adults

    Brain, behavior, and immunity

  2. IL-6 is linked with worse executive function in humans (major surgery) (β=0.074, P<0.001).

    “Changes in interleukin-6 levels were associated with changes in Trail Making Test B over 1 yr in a generalised additive model (β=0.074, P<0.001)”

    Humansmajor surgery1 yrn = 170

    Resolution of elevated interleukin-6 after surgery is associated with return of normal cognitive function

    British journal of anaesthesia

Frailty

mediatesin humans1no changein humans1

2 studies
  1. IL-6 is linked with frailty in humans (ACME 0.052 (95% CI 0.020-0.087, P = .002)).

    “association between DII and frailty was significantly mediated by IL-6 (average causal mediation effect [ACME], 0.052; 95% confidence interval, 0.020-0.087; P = .002)”

    Humansin patients with colorectal cancer, adjusting for age, sex, BMI, education, smoking, and energyn = 126

    Association between dietary inflammatory potential and frailty is mediated by inflammation among patients with colorectal cancer: A cross-sectional study

    Nutrition research (New York, N.Y.)

  2. IL-6 was not clearly linked with frailty in humans (rural Bai people).

    “The SNPs of rs1524107, rs1800796, and rs10499563 in the IL-6 gene were not associated with the occurrence of frailty”

    Humansrural Bai peoplen = 231

    Association of single nucleotide polymorphisms of IL-6 gene with frailty in the Chinese Bai nationality

    Medicine

Psychomotor processing speed

no changein humans1downin humans1

1 study
  1. IL-6 was not clearly linked with psychomotor processing speed in humans (γ = -.01, p = .45).

    “Higher mean IL-6 was associated with slower TMT-A performance for women (γ = .036, p = .04) but not men (γ = -.01, p = .45).”

    Humansmales

    Higher interleukin-6 (IL-6) is associated with decline in psychomotor processing speed but not executive functioning in older adults: Gender-specific effects

    The journals of gerontology. Series B, Psychological sciences and social sciences

  2. IL-6 is linked with worse psychomotor processing speed in humans (γ = .036, p = .04).

    “Higher mean IL-6 was associated with slower TMT-A performance for women (γ = .036, p = .04) but not men”

    Humansfemales

    Higher interleukin-6 (IL-6) is associated with decline in psychomotor processing speed but not executive functioning in older adults: Gender-specific effects

    The journals of gerontology. Series B, Psychological sciences and social sciences

Cardiovascular risk reclassification separation

upin humans1

1 study
  1. IL-6 is linked with better cardiovascular risk reclassification separation in humans Among reclassified individuals; compared with high-sensitivity C-reactive protein (Event-rate separation 1.15 versus 0.54 per 1,000 person-years).

    “Among reclassified individuals, IL-6 separated upward- versus downward-reclassified event rates more than twice as effectively as hsCRP (1.15 vs 0.54 per 1,000 person-years).”

    HumansAmong reclassified individuals; compared with high-sensitivity C-reactive protein10 years

    Inflammation protein may help refine heart disease risk estimates

    AHA Scientific Sessions 2026 abstract

Cardiovascular disease risk

mediatesin humans1

1 study
  1. IL-6 is linked with cardiovascular disease risk in humans (23.8% mediated by IL-6; 35.7% jointly mediated by IL-6, CRP, and BMI).

    “Multi-mediator path analysis attributed 35.7% of the total UPF-CVD association (HR 1.080) to the three joint mediators (IL-6: 23.8%, CRP: 10.4%, BMI: 1.6%).”

    Humansmediation of the association between ultra-processed food consumption and cardiovascular disease

    Inflammation may link ultra-processed foods to heart disease

    AHA Scientific Sessions 2026 abstract

More on Cardiovascular disease risk

VACS 2.0 Frailty Index

no changein humans1

1 study
  1. IL-6 was not clearly linked with VACS 2.0 Frailty Index in humans (HIV-negative older Veterans).

    “Plasma levels of IL-6 and T cell markers of exhaustion and senescence were not correlated with the VACS 2.0 Frailty Index.”

    HumansHIV-negative older Veteransplasman = 30

    VACS 2.0 Frailty Index Correlates with Soluble TNF Receptor Levels in Aging Veterans

    Frontiers in aging

More on VACS 2.0 Frailty Index

Soluble LRP1

downin silico1

1 study
  1. IL-6 decreases soluble LRP1 in silico (Mendelian randomization) (p = 1.13 × 10 − 15).

    “reduced LRP1 was reciprocally associated with elevated inflammatory markers (IL-6→LRP1, p = 1.13 × 10 − 15 )”

    In silicoMendelian randomization

    Air pollution and lung disease are linked to Alzheimer's risk

    Journal of neuroinflammation

More on Soluble LRP1

Physical function and physical activity changes

no changein humans1

1 study
  1. IL-6 showed no clear effect on physical function and physical activity changes in humans (changes over a 16-week physical activity intervention).

    “No associations with changes in hs-CRP, IL-6, total cholesterol, HDL, transferrin, GDF-15, and NT-proBNP were found.”

    Human trialchanges over a 16-week physical activity intervention16 weeksn = 339

    Association between changes in physical performance and changes in biomarkers during a physical activity intervention in older adults - an exploratory study

    Experimental gerontology

All 77

Upstream

38

Age

upin humans1downin humans1upin mice1

3 studies
  1. Age is linked with higher IL-6 in humans (COVID-19) (p = 0.026).

    “Patients aged ≥65 years had significantly higher levels of IL-1β ( p = 0.036), IL-1Ra ( p = 0.025), IL-6 ( p = 0.026), IL-8 ( p = 0.014), IL-10 ( p = 0.005)”

    HumansCOVID-19

    Immunosenescence shapes the inflammatory response to viral infection in vaccinated and unvaccinated patients

    Research SquarePreprint

  2. Age is linked with lower IL-6 in humans (aged vs younger CRS patients) (significant reduction, p < 0.01).

    “Compared to younger patients with CRS, aged CRS patients exhibited a significant reduction in IL-6 levels (p < 0.01)”

    Humansaged vs younger CRS patientsnasal mucusn = 31

    Age-related changes of inflammatory cytokines in nasal secretion of patients with chronic rhinosinusitis

    Respiratory medicine

  3. Age increases IL-6 in mice with aging.

    “With aging, IL-6 was the only marker significantly elevated in both sexes.”

    Animalswith agingbrain

    Influence of Age and Sex on M1-Type Pro-Inflammatory Gene Expression Following Cerebral Ischemia and Reperfusion

    Physiology

Cellular senescence

upin human cells2

2 studies
  1. Cellular senescence increases IL-6 in cultured human apical papilla cells.

    “Interleukin-6 expression increased and TGF-β decreased”

    Cellsin cultured human apical papilla cells

    Effects of Human Apical Papilla Cell Senescence on Repair-related Functions in Regenerative Endodontics

    Journal of endodontics

  2. Cellular senescence increases IL-6 in stress-induced senescence.

    “Our analysis confirmed the upregulation of established aging markers, such as IL-6, PAI-1, and IGFBP7.”

    Cellsin stress-induced senescence

    Influence of Stress-Induced Senescence on the Secretome of Primary Mesenchymal Stromal Cells

    Biomolecules

More on Cellular senescence

CGAS

downin mice1

1 study
  1. CGAS decreases IL-6 in mice (shown by knockout in liver ischemia–reperfusion injury).

    “Additionally, aged cGAS-/- mice exhibited a significant surge in serum IL-6 and gut barrier dysfunction (FITC-dextran assay) at 6 h post-injury.”

    Animalsshown by knockout in liver ischemia–reperfusion injury6 h post-injuryfemales

    Older female mice lacking a DNA sensor had worse liver injury

    Biology

More on CGAS

DNAm PAI-1

mediatesin humans1

1 study
  1. DNAm PAI-1 is linked with IL-6 in humans (30.0% of association mediated; FDR p=0.030).

    “In sex- and race-adjusted models, DNAm PAI-1 mediated 30.0% of the association with IL-6 (N=232; FDR p=0.030)”

    HumansAssociation of neighborhood building conditions rated fair or below with IL-6; adjusted for sex and self-reported racen = 232

    Epigenetic Mediation of Early-Life Exposures and Young-Adult Cardiometabolic Risk in the Future of Families and Child Wellbeing Study

    AHA Scientific Sessions 2026 abstract

More on DNAm PAI-1

DunedinPoAm38

mediatesin humans1

1 study
  1. DunedinPoAm38 is linked with IL-6 in humans (Association of food stamp receipt with IL-6; adjusted for sex and self-reported race) (23.2% of total effect mediated; FDR p=0.028).

    “with 23.2% of the sex- and race-adjusted total effect mediated by age 15 PoAm38 on 450K (N=355; FDR p=0.028).”

    HumansAssociation of food stamp receipt with IL-6; adjusted for sex and self-reported race450Kn = 355

    Epigenetic Mediation of Early-Life Exposures and Young-Adult Cardiometabolic Risk in the Future of Families and Child Wellbeing Study

    AHA Scientific Sessions 2026 abstract

More on DunedinPoAm38

Coronary artery disease

upin humans1

1 study
  1. Coronary artery disease is linked with higher IL-6 in humans.

    “Across the CAD spectrum, a stepwise increase in systemic IL-6, TNF-α, MCP-1, ICAM-1, and VCAM-1 were observed, reaching peak levels during acute STEMI.”

    Humansstepwise rise from healthy subjects through stable CAD to acute STEMI; MCP-1, ICAM-1 and VCAM-1 rose similarly

    Gliflozin therapy attenuates persistent systemic inflammation and monocyte metabolic dysfunction post-ACS: a comparative study across the CAD spectrum

    ESC Congress 2026 abstract

More on Coronary artery disease

TP53

downin mice1

1 study
  1. TP53 decreases IL-6 in mice (Transgenic expression in a mouse model of Hutchinson-Gilford progeria syndrome).

    “reduced the expression of p21 Waf1/Cip1 (a mediator of cellular senescence), IL-6 (a proinflammatory cytokine), and γ-H2AX”

    AnimalsTransgenic expression in a mouse model of Hutchinson-Gilford progeria syndromeΔ133p53α isoformmultiple tissues

    Human protein variant eased signs of progeria in mice

    NPJ aging

More on TP53

Abdominal aortic aneurysm

upin silico1

1 study
  1. Abdominal aortic aneurysm increases IL-6 in abdominal aortic aneurysm.

    “IL1B, IL6 (both upregulated)”

    In silicoin abdominal aortic aneurysm

    Identification of Cellular Senescence-Related Hub Genes and Their Association with Immune Infiltration in Abdominal Aortic Aneurysm: A Comprehensive Bioinformatics Analysis

    Research SquarePreprint

More on Abdominal aortic aneurysm

Anemia

upin humans1

1 study
  1. Anemia is linked with higher IL-6 in humans (CHF patients with anemia vs without anemia) (9.54 ± 0.67 vs 6.93 ± 0.97 pg/ml).

    “the average IL-6 level was (9.54 ± 0.67) pg/ml, which is significantly higher than in the CHF group without anemia (6.93 ± 0.97) pg/ml (p = 0.004)”

    HumansCHF patients with anemia vs without anemia

    Elevated Levels for Interleukin-6 as a Marker of Death Risk in Elderly and Senile Patients with CHF and Anemia: A Prospective Cohort Study

    Russian Journal of Geriatric Medicine

More on Anemia

Low LGV

upin C. hircus1

1 study
  1. Low LGV increases IL-6 in C. hircus (LPS challenge).

    “Low_LGV goats exhibited stronger acute inflammatory responses with greater IL-6 and IFN-γ concentrations during the early hours post-challenge”

    AnimalsLPS challengefemales

    Effect of longevity genotype on acute phase response to a lipopolysaccharide challenge in dairy goats

    PloS one

Normal weight obesity

upin humans1

1 study
  1. Normal weight obesity increases IL-6 in humans (fasting).

    “Fasting IL-6 was higher in NWO-O relative to NWL-Y (p < 0.05).”

    Human trialfastingbloodn = 29

    Postprandial Cardiometabolic Parameters in Older Adults with Normal-Weight Obesity: A Cross-Sectional Pilot Study

    Metabolites

All 38

Associations

223

Mortality

upin humans17downin humans2mixedin humans1+1% risk of death per unitHR 0.52–3.5

20 studies
  1. IL-6 predicts mortality in humans (IL- 6 level >= 11.2 pg/mL vs < 11.2pg/mL) (adjusted HR 3.5, 95% CI 1.95-6.28, p < 0.001).

    “Compared to patients with low IL- 6 level < 11.2pg/mL, patients with high levels had a more than 3-fold increase in mortality at 30-days (adjusted HR 3.5, 95% CI 1.95-6.28, p < 0.001)”

    Human trialIL- 6 level >= 11.2 pg/mL vs < 11.2pg/mL30-dayn = 996

    Comparison of the inflammatory biomarkers IL- 6, TNF-α, and CRP to predict the effect of nutritional therapy on mortality in medical patients at risk of malnutrition : A secondary analysis of the randomized clinical trial EFFORT

    Journal of inflammation (London, England)

  2. IL-6 is associated with mortality in humans (IL-6 at or above cohort- and sex-specific medians; adjusted for CKM stage) (HR 1.48, 95% CI 1.36–1.61).

    “Higher IL-6 and hsCRP were each associated with higher cardiovascular and mortality risks independent of early-stage CKM syndrome.”

    HumansIL-6 at or above cohort- and sex-specific medians; adjusted for CKM stagen = 9,894

    Inflammation and the Association of Early-stage Cardiovascular-Kidney-Metabolic Syndrome with Incident Cardiovascular Disease and All-cause Mortality: Findings from the CARDIA and MESA Cohorts

    American heart journal

  3. IL-6 is associated with mortality in elderly COVID-19 non-survivors.

    “Additionally, five cytokines-GRO-α, IL-6, IL-8, IP-10, and TSLP-showed higher levels in non-survivors.”

    Humansin elderly COVID-19 non-survivors

    Plasma metabolites link to T-cell senescence in elderly COVID-19

    Biomedicines

  4. IL-6 is associated with mortality in humans (recently diagnosed type 2 diabetes without prevalent CVD) (HR 1.38, 95% CI 1.31, 1.45).

    “A 1-SD increase in log-IL-6 (1.98 pg/mL), log-TNF-α (1.40 pg/mL) and log-hsCRP (3.28 mg/L) was associated with HRs of 1.16 (95% CI 1.09, 1.23)”

    Humansrecently diagnosed type 2 diabetes without prevalent CVD

    Low-grade inflammation predicts major cardiovascular events and mortality in recently diagnosed type 2 diabetes: A Danish nationwide cohort study

    European journal of preventive cardiology

  5. IL-6 is linked with a higher risk of mortality in humans (CHF patients with anemia; 4th IL-6 quartile; univariate Cox regression) (1.087 (1.007–1.174)).

    “revealed a significant effect of IL-6 on the risk of death from cardiovascular and non-cardiovascular causes in 4QR patients”

    HumansCHF patients with anemia; 4th IL-6 quartile; univariate Cox regressionup to 24 months

    Elevated Levels for Interleukin-6 as a Marker of Death Risk in Elderly and Senile Patients with CHF and Anemia: A Prospective Cohort Study

    Russian Journal of Geriatric Medicine

  6. IL-6 predicts mortality in humans (CHF patients with anemia; 4th vs 1st IL-6 quartile) (higher mortality in 4th than 1st IL-6 quartile, p = 0.04022).

    “a higher mortality rate of patients in the 4th quartile range (QR) of IL-6 levels (12.5–39.4 pg/ml), than in 1QR (1.10–5.00 pg/ml) (p = 0.04022).”

    HumansCHF patients with anemia; 4th vs 1st IL-6 quartileup to 24 months

    Elevated Levels for Interleukin-6 as a Marker of Death Risk in Elderly and Senile Patients with CHF and Anemia: A Prospective Cohort Study

    Russian Journal of Geriatric Medicine

  7. IL-6 is linked with a higher risk of mortality in humans (per 1-SD increase, endpoint-specific analysis) (HR 1.17 (95% CI 1.14-1.20)).

    “IL-6 for cardiovascular death (HR 1.20, 1.12-1.29) and all-cause mortality (HR 1.17, 1.14-1.20)”

    Humansper 1-SD increase, endpoint-specific analysisn = 34,064

    Joint associations of Interleukin-6 and apolipoprotein B with major adverse cardiovascular events in the UK biobank

    Progress in cardiovascular diseases

  8. IL-6 predicts mortality in humans after adjustment for CURB-65 in logistic regression.

    “After adjustment for CURB-65 in logistic regression, only IL-6 independently predicted mortality”

    Humansafter adjustment for CURB-65 in logistic regression

    Th1/Th2/Th17 Cytokines as Mortality Predictors in Older Adults with COVID-19 Pneumonia

    Jundishapur Journal of Microbiology

  9. IL-6 is linked with a higher risk of mortality in humans (elevated IL-6).

    “Ever smoking, hypertension and elevated IL-6 were significantly associated with increased risk of mortality and MACE.”

    Humanselevated IL-6

    Prognostic value of ankle-brachial index and cardio-ankle vascular index for mortality and cardiovascular events in older people with HIV on long-term ART

    HIV medicine

  10. IL-6 is linked with a higher risk of mortality in humans (univariate Cox regression models) (1% increase in risk of death per unit).

    “each unit increase in IL-6 levels was associated with a 1% increase in the risk of death”

    Humansunivariate Cox regression modelsbloodper unit increase in levels

    IL-6 and TNF-α as Predictors of Mortality in Octogenarians: Evidence from a Brazilian Cohort

    Research SquarePreprint

All 21

Frailty

upin humans16mixedin humans3OR 1.14–4.64

19 studies
  1. IL-6 is associated with frailty in humans (patients with pulmonary arterial hypertension).

    “Higher levels of IL-6 were significantly associated with odds of frailty”

    Humanspatients with pulmonary arterial hypertension

    Frailty in Pulmonary Arterial Hypertension: A Cohort Study

    Annals of the American Thoracic Society

  2. Frailty is associated with IL-6 in humans (P = 0.005).

    “hsCRP and IL-6 levels showed significant elevation with increasing frailty severity ( P < 0.001 and P = 0.005, respectively).”

    Humansn = 387

    Frailty through the Lens of Chronic Low-grade Inflammation in Older Adults: A Cross-sectional Study

    Journal of The Indian Academy of Geriatrics

  3. IL-6 is associated with frailty in humans (OR 1.14 (95% CI 1.01–1.30)).

    “Elevated IL-6 (OR = 1.14, 1.01–1.30) and TNF-α (OR = 1.21, 1.07–1.36) correlated with frailty.”

    Humans

    The Association between Frailty and Inflammatory Biomarkers in the Elderly

    GSA 2025 abstract

  4. IL-6 is linked with a higher risk of frailty in humans (chronic obstructive pulmonary disease) (OR 1.454, 95% CI 1.113–2.006).

    “serum interleukin-6 (OR = 1.454, 95%CI: 1.113 ~ 2.006) and serum hemoglobin concentration (OR = 0.675, 95%CI: 0.225 ~ 0.901) were the influencing factors of the frailty of older adults with COPD”

    Humanschronic obstructive pulmonary diseasen = 224

    Frailty in older adults with chronic obstructive pulmonary disease: preliminary findings of prevalence and care priorities

    BMC geriatrics

  5. IL-6 is linked with a higher risk of frailty in humans (patients undergoing abdominal surgery) (OR=1.76).

    “elevated interleukin-6 (OR=1.76).”

    Humanspatients undergoing abdominal surgeryn = 790

    Development and Validation of Nomogram to Predict Frailty for Older Patients Undergoing Abdominal Surgery

    Clinical interventions in aging

  6. IL-6 is linked with a higher risk of frailty in humans (hospitalized older adults) (P < 0.001).

    “After adjustment, high levels of IL-6, hs-CRP, and IL-10 in frail older adults were significantly linked to frailty risk (all P < 0.001).”

    Humanshospitalized older adultsn = 4,438

    Sex Differences in the Association Between Inflammatory Biomarkers (Hs-CRP, IL-6, IL-10, TNF-α) and Frailty in Hospitalized Adults Aged ≥65 in Taizhou, China: A Cross-Sectional Study

    Clinical interventions in aging

  7. IL-6 is associated with frailty in humans (GG; OR = 4.64, 95%IC = 3.35-6.43).

    “IL-6, codominant rs1800796 (GC; OR = 2.10, 95%CI = 1.60-2.77), GG; OR = 4.64, 95%IC = 3.35-6.43; p < 0.001)”

    Humans

    Genetic association of proinflammatory cytokines in the pathogenesis of frailty syndrome: an application of ordinal logistic regression model

    BMC geriatrics

  8. IL-6 is associated with frailty in patients with multiple sclerosis (OR = 1.46; 95 % CI = 1.02-1.93).

    “serum IL-6 independently correlated with frailty in MS patients (OR = 1.46; 95 % CI = 1.02-1.93; P = 0.003).”

    Humansin patients with multiple sclerosis

    Association between frailty and inflammatory cytokines in patients with multiple sclerosis: a case-control study

    Cytokine

  9. IL-6 predicts frailty in humans (severe aortic stenosis).

    “notably, in the multivariate model, IL-6 emerged as a significant independent predictor of frailty (OR 1.037; CI 1.001-1.074, p = 0.043).”

    Humanssevere aortic stenosisn = 191

    Frailty in Older Adults with Severe Aortic Stenosis: The Role of Systemic Inflammation and Calcium Homeostasis

    Journal of clinical medicine

  10. IL-6 is associated with frailty in humans (older cancer survivors).

    “Factors associated with frailty progression included older age, lower education, more comorbidities, and higher IL-6 and CRP levels.”

    Humansolder cancer survivorsn = 1,219

    Frailty transitions and associated factors in older cancer survivors in the USA: using a multi-state modeling

    Journal of cancer survivorship : research and practice

All 19

Sarcopenia

upin humans8no changein humans1OR 1.17

9 studies
  1. IL-6 is associated with sarcopenia in humans (maintenance hemodialysis) (OR 1.17).

    “elevated IL-6 (OR 1.17, p = 0.005) with sarcopenia.”

    Humansmaintenance hemodialysisn = 61

    Cytokines and hematological indices as potential markers of low cardiorespiratory fitness and sarcopenia in hemodialysis patients

    Clinical nephrology

  2. IL-6 is associated with sarcopenia in humans (p = 0.04).

    “Elevated IL-6 and GDF-15 levels were significantly correlated with the presence of sarcopenia (p = 0.04 and p = 0.03, respectively)”

    Humansn = 179

    Interplay of IL-6, GDF-15 and Sarcopenia in Patients With Bladder Cancer Undergoing Radical Cystectomy and Its Implications on Survival

    Journal of cachexia, sarcopenia and muscle

  3. Sarcopenia is associated with IL-6 in humans (adjusted for BMI, age, and disease duration) (p < 0.05).

    “the cytokines IL-1α, IL-6, and TNFβ concentrations were significantly higher (p < 0.05) in patients with sarcopenia, adjusted for BMI, age, and disease duration.”

    Humansadjusted for BMI, age, and disease durationfemalesn = 165

    Inflammatory profile in patients with rheumatoid arthritis and sarcopenia

    Clinical rheumatology

  4. Sarcopenia is associated with IL-6 in humans.

    “Furthermore, the sarcopenic patients had higher levels of TNF-α (p=0007), IL-1β (p<0.001) and IL-6 (p<0.001).”

    Humans12-week intervention period

    Enhanced serum levels of tumor necrosis factor-α, interleukin-1β, and -6 in sarcopenia: alleviation through exercise and nutrition intervention

    Aging

  5. Sarcopenia is associated with IL-6 in humans (compared with non-sarcopenic participants) (p<0.001).

    “sarcopenic patients exhibited higher levels of TNF-α (p=0.007), IL-1β (p<0.001), and IL-6 (p<0.001)”

    Humanscompared with non-sarcopenic participants

    Enhanced serum levels of tumor necrosis factor-α, interleukin-1β, and -6 in sarcopenia: alleviation through exercise and nutrition intervention

    Aging

  6. Sarcopenia is associated with IL-6 in humans (heart failure).

    “sarcopenia was associated with higher serum levels of IL-6”

    Humansheart failuren = 90

    Sarcopenia: Inflammatory and Humoral Markers in Older Heart Failure Patients

    Arquivos brasileiros de cardiologia

  7. Sarcopenia is associated with IL-6 in humans after trimming 6 studies for publication bias (SMD 0.12 (95% CI -0.38 to 0.61)).

    “following trim of 6 studies, an insignificant effect between groups was observed (SMD, 0.12; 95% CI, -0.38 to 0.61)”

    Reviewafter trimming 6 studies for publication bias

    Differences in Circulating Inflammatory Markers in Older Adults With and Without Sarcopenia: A Systematic Review and Meta-Analysis

    Journal of the American Medical Directors Association

  8. Sarcopenia is associated with IL-6 in patients with sarcopenia compared to controls.

    “Patients with sarcopenia exhibited elevated interleukin-6 (IL-6), C-reactive protein (CRP), and tumor necrosis factor-alpha (TNF-α) levels compared to controls”

    Reviewin patients with sarcopenia compared to controls

    Biomarkers for sarcopenia, muscle mass, muscle strength, and physical performance: an umbrella review

    Journal of translational medicine

  9. Sarcopenia is associated with IL-6 in humans with sarcopenia vs without sarcopenia (SMD = 0.31; 95% CI 0.18, 0.44).

    “Meta-analysis revealed significantly elevated serum IL-6 levels in older adults with sarcopenia compared with those without sarcopenia (SMD = 0.31; 95% CI 0.18, 0.44).”

    Reviewwith sarcopenia vs without sarcopenian = 3,902

    Association of interleukin-6 with sarcopenia and its components in older adults: a systematic review and meta-analysis of cross-sectional studies

    Annals of medicine

  10. IL-6 is associated with sarcopenia in humans (0.91 [0.59, 1.24]).

    “IL-6 (95 % CI: 0.91 [0.59, 1.24], P < 0.05)”

    Review

    Exploring the impact of interleukins on sarcopenia development: A systematic review and meta-analysis

    Experimental gerontology

More on Sarcopenia

Cognitive function

downin humans7upin humans1

7 studies
  1. IL-6 is associated with cognitive function in humans (r = -0.313).

    “Furthermore, there was a significant negative correlation between changes in IL-6 level and changes in memory search score when combining experimental and control group (r = -0.313, p = 0.038) (see Additional file ).”

    Human trial12 weeksn = 70

    Resistance training's impact on blood biomarkers and cognitive function in older adults with low and high risk of mild cognitive impairment: a randomized controlled trial

    European review of aging and physical activity : official journal of the European Group for Research into Elderly and Physical Activity

  2. IL-6 is associated with cognitive function in the total group of participants.

    “IL-6 level increases were associated with improvements in response time on the memory search test in the total group of participants.”

    Human trialin the total group of participants12 weeksn = 52

    Resistance training's impact on blood biomarkers and cognitive function in older adults with low and high risk of mild cognitive impairment: a randomized controlled trial

    European review of aging and physical activity : official journal of the European Group for Research into Elderly and Physical Activity

  3. IL-6 is associated with cognitive function in humans.

    “Increased levels of IL-6 were also associated with poorer performance in all cognitive domains, but these associations did not survive multiple comparisons correction.”

    Humansn = 1,806

    Interleukin-6 is associated with white matter hyperintensities and cognition independent of Alzheimer's disease plasma biomarkers-HABS-HD

    Journal of Alzheimer's disease : JAD

  4. IL-6 is associated with cognitive function in aging veterans with a history of TBI.

    “with higher levels correlating with accelerated cognitive decline.”

    Humansin aging veterans with a history of TBIplasma astrocyte-derived small extracellular vesiclesmales

    Inflammatory and Complement Biomarkers of Cognitive Decline in Astrocyte‐Derived Extracellular Vesicles from the Vietnam Era Twin Study of Aging

    AAIC 2025 abstract

  5. IL-6 is associated with cognitive function in humans.

    “IL-6, IL-8 and TNF-α levels were negatively associated with T. gondii antibody level and cognitive performance.”

    Humans

    Changes of cognitive functions and proinflammatory cytokines across the lifespan in latent Toxoplasma gondii infection

    Brain, behavior, & immunity - health

  6. IL-6 predicts cognitive function in humans among those with greater levels of friendship quality.

    “higher IL-6 levels at Time 1 predicted poorer cognitive performance a decade later, but only among those with greater levels of friendship quality”

    Humansamong those with greater levels of friendship qualityten yearsn = 929

    Biopsychosocial contexts influence adult cognitive function concurrently and longitudinally

    Brain, behavior, & immunity - health

  7. IL-6 is associated with cognitive function in humans (type 2 diabetes mellitus) (r = -0.421, P = 0.015).

    “IL-6 was negatively correlated with the MoCA score (r = -0.421, P=0.015).”

    Humanstype 2 diabetes mellitusn = 44

    Cognitive decline in elderly patients with type 2 diabetes is associated with glycated albumin, ratio of Glycated Albumin to glycated hemoglobin, and concentrations of inflammatory and oxidative stress markers

    Heliyon

  8. IL-6 is associated with cognitive function in humans (cross-sectional).

    “Higher IL-6 (OR: 1.33; 1.06, 1.66, p = 0.01), TNF-α (OR: 1.35; 1.09, 1.67, p = 0.01) and IL-6:IL-10 Ratio (OR: 1.43; 1.17, 1.74, p = 0.001) were cross-sectionally associated with impaired global RBANS performance.”

    Humanscross-sectionalserumn = 3,270

    Low-Grade systemic inflammation is associated with domain-specific cognitive performance and cognitive decline in older adults: Data from the TUDA study

    Neurobiology of aging

Age

upin humans6

6 studies
  1. IL-6 is associated with age in humans (discovery cohort).

    “Four cytokines (IL‐4, IL‐5, IL‐6, IL‐12p70) were significantly correlated with age”

    Humansdiscovery cohortn = 439

    Age-linked immune endotypes are associated with COPD risk

    Journal of inflammation research

  2. Age is associated with IL-6 in heavily treatment-experienced individuals.

    “Interleukin-6 (IL-6) was lower in VT and positively correlated with age.”

    Humansin heavily treatment-experienced individuals

    Age and viral replication, not vertical HIV acquisition, drive inflammation and T-cell dysfunction in heavily treatment experienced: data from the Prestigio Registry

    AIDS (London, England)

  3. Age is associated with IL-6 in humans (biomass smoke exposure) (R = 0.95, p < 0.001).

    “Multivariate analysis revealed strong positive correlations between age and inflammatory cytokines: IL-6 (R = 0.95, p < 0.001)”

    Humansbiomass smoke exposurefemales

    Mitochondrial Epigenetic Alterations Induced by Biomass Smoke Exposure and Their Role in Age-Related Breast Cancer Risk: A Machine Learning-Based Predictive Study

    Asian Pacific journal of cancer prevention : APJCP

  4. Age is associated with IL-6 in people with multiple sclerosis; consistent with inflammaging.

    “A positive correlation was found between age and the levels of IL-6, TNF-α, and CRP in pwMS”

    Humansin people with multiple sclerosis; consistent with inflammagingn = 146

    Aging-dependent immunological changes in multiple sclerosis

    Frontiers in immunology

  5. IL-6 is associated with age in humans (Tsimane population, primarily cross-sectional sample) (β = 0.013, p < 0.01).

    “IL-6 was positively associated with age (β = 0.013, p < 0.01).”

    HumansTsimane population, primarily cross-sectional samplen = 714

    Inflammaging is minimal among forager-horticulturalists in the Bolivian Amazon

    Proceedings. Biological sciences

  6. Age is associated with IL-6 in humans (post-high-fat meal) (b = 0.029, p = 0.010).

    “age was positively associated with IL-6 incremental AUC when examined continuously (b = 0.029; p = 0.010).”

    Humanspost-high-fat mealn = 56

    Postprandial inflammation across the aging spectrum

    The journal of nutrition, health & aging

Heart failure

upin humans3HR 1.2–1.69

3 studies
  1. IL-6 predicts heart failure in humans (per 1-SD higher log[IL-6] in adults with T2D and overweight/obesity) (HR: 1.43; 95% CI: 1.16-1.75).

    “Higher IL-6 was significantly associated with higher risk of incident HF in the overall cohort (HR: 1.43; 95% CI: 1.16-1.75 per 1-SD higher log[IL-6])”

    Human trialper 1-SD higher log[IL-6] in adults with T2D and overweight/obesityn = 1,507

    Residual Inflammatory Risk of Heart Failure and Atherosclerotic CVD in Diabetes: Look AHEAD Ancillary Study

    JACC. Heart failure

  2. IL-6 is associated with heart failure in humans (IL-6 at or above cohort- and sex-specific medians; adjusted for CKM stage) (HR 1.69, 95% CI 1.41–2.03).

    “Higher IL-6 and hsCRP were each associated with higher cardiovascular and mortality risks independent of early-stage CKM syndrome.”

    HumansIL-6 at or above cohort- and sex-specific medians; adjusted for CKM stagen = 9,894

    Inflammation and the Association of Early-stage Cardiovascular-Kidney-Metabolic Syndrome with Incident Cardiovascular Disease and All-cause Mortality: Findings from the CARDIA and MESA Cohorts

    American heart journal

  3. IL-6 is linked with a higher risk of heart failure in humans (HR 1.20, 95% CI 1.08-1.34).

    “All 4 biomarkers were independently associated with incident HF (IL-6: hazard ratio [HR], 1.20 [95% CI, 1.08-1.34]”

    Humansapproximately 16 yearsn = 6,785

    Inflammatory burden is linked to incident heart failure

    medRxivPreprint

More on Heart failure

Atherosclerotic cardiovascular disease

upin humans3HR 1.48–1.54

3 studies
  1. IL-6 is associated with atherosclerotic cardiovascular disease in humans (IL-6 at or above cohort- and sex-specific medians; adjusted for CKM stage) (HR 1.48, 95% CI 1.33–1.64).

    “IL-6 at or above the median was associated with higher risks of atherosclerotic CVD (hazard ratio, 1.48; 95% CI, 1.33–1.64)”

    HumansIL-6 at or above cohort- and sex-specific medians; adjusted for CKM stagen = 9,894

    Inflammation and the Association of Early-stage Cardiovascular-Kidney-Metabolic Syndrome with Incident Cardiovascular Disease and All-cause Mortality: Findings from the CARDIA and MESA Cohorts

    American heart journal

  2. IL-6 is linked with a higher risk of atherosclerotic cardiovascular disease in humans after adjusting for LE8 metrics and demographics (HR 1.54 [1.05-2.25], p = 0.03).

    “Increased IL-6 was independently associated with ASCVD (HR 1.54 [1.05-2.25], p = 0.03)”

    Humansafter adjusting for LE8 metrics and demographics12 yearsn = 1,869

    Impact of life's essential eight and inflammatory markers on long-term cardiovascular disease risk and all-cause mortality: Insights from the Heart SCORE study

    Heart & lung : the journal of critical care

  3. IL-6 raises the risk of atherosclerotic cardiovascular disease in observational studies.

    “IL-6 has been identified as a source of residual risk for ASCVD”

    Reviewin observational studies

    The role of IL-6 in atherosclerosis: a narrative review

    Frontiers in cardiovascular medicine

More on Atherosclerotic cardiovascular disease

Cognitive impairment

upin humans3OR 1.12–1.87

3 studies
  1. IL-6 is associated with cognitive impairment in humans (log10-transformed plasma IL-6; adjusted analysis) (OR = 1.87, 95% CI [1.31, 2.68]).

    “Higher plasma IL-6 was associated with greater odds of cognitive impairment in the full sample”

    Humanslog10-transformed plasma IL-6; adjusted analysisn = 2,187

    Blood protein linked to cognitive impairment in older adults

    Frontiers in dementia

  2. IL-6 is associated with cognitive impairment in humans (OR 1.12 (95% CI 1.02-1.22)).

    “A doubling of IL-6 was associated with a 12% higher odds of cognitive impairment (OR = 1.12, 95% CI: 1.02-1.22)”

    Humansper doubling of IL-6n = 3,346

    DNA methylation age acceleration mediates the relationship between systemic inflammation and cognitive impairment

    Epigenomics

  3. Cognitive impairment is associated with IL-6 in older adults (12% in normal vs 30-55% in impaired).

    “12% of cognitively normal older adults had IL-6 levels in the highest tertile, but this increased in cognitively impaired cohorts-36% in Alzheimer's disease, 55% mixed dementia, 30% mild cognitive impairment, and 39% vascular mild cognitive impairment.”

    Humansin older adultsn = 514

    Peripheral inflammation in a Canadian cohort of neurodegenerative conditions: Occurrence, determinants, and impact

    Journal of Alzheimer's disease : JAD

More on Cognitive impairment

Older age

upin humans1upin rats1upin rhesus monkeys1

3 studies
  1. Older age is associated with IL-6 in humans (Baseline, before heat exposure) (2.67 versus 1.59 log pg/mL in older versus young adults).

    “At baseline both IL-6LOG and CRP concentrations were higher in the older”

    HumansBaseline, before heat exposure

    Markers of enterocyte damage, microbial translocation, and systemic inflammation following 9 h of heat exposure in young and older adults

    Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme

  2. IL-6 is associated with older age in rhesus monkeys.

    “Systemic inflammatory and metabolic stress proteins, including IL6 and GDF15, were higher in older animals”

    Animalsplasma

    Aging rhesus macaques display distinct fluid proteomic signatures of senescence and neuropathology

    GeroScience

  3. Older age is associated with IL-6 in rats (elder versus young adult Wistar albino rats).

    “TNF-α, IL-6, GRP78, and MAPK protein levels were shown to increase significantly in aged rat kidneys, whereas occludin levels decreased significantly.”

    Animalselder versus young adult Wistar albino ratskidney

    The effect of NF-kB and MAPK mediated Proinflammatory microenvironment on renal aging and amyloid deposition in elder rats

    Scientific reports

Obesity

upin humans3

3 studies
  1. Obesity is associated with IL-6 in humans (obesity).

    “The markers that were higher in obese women were GSSG, protein carbonylation, IL-6, and S100B”

    Humansobesityserumfemalesn = 156

    Biomarkers of Oxidative Stress, Inflammation, and Brain Damage in Mexican Women over 60 Years of Age with Obesity

    Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion

  2. Obesity is associated with IL-6 in humans (obese vs overweight group).

    “also higher serum IL-6 concentration than the overweight group”

    Humansobese vs overweight groupserumfemalesn = 70

    Association among inflammaging, body composition, physical activity, and physical function tests in physically active women

    Frontiers in medicine

  3. Obesity is associated with IL-6 in humans.

    “overweight and obese middle-aged and elderly individuals show elevated levels of inflammatory markers like CXCL-16, IL-6, and adipokines compared to normal weight counterparts.”

    Review

    Obesity-Related Inflammatory Biomarkers in the Elderly Population

    Cells

More on Obesity

GrimAge2

upin humans1

1 study
  1. IL-6 is associated with GrimAge2 in cystic fibrosis (FDR adjusted p < 0.05).

    “Higher IL-6, IL-1β, and calprotectin were significantly associated with greater age acceleration after FDR correction (FDR adjusted p < 0.05).”

    Human trialin cystic fibrosisone-year follow-upn = 8

    Elexacaftor/tezacaftor/ivacaftor treatment is associated with epigenetic age deceleration in cystic fibrosis

    bioRxivPreprint

  2. IL-6 is associated with GrimAge2 in humans.

    “Greater age acceleration was associated with higher IL-6, IL-1{beta}, and calprotectin concentrations.”

    Human trial

    Elexacaftor/tezacaftor/ivacaftor treatment is associated with epigenetic age deceleration in cystic fibrosis

    bioRxivPreprint

More on GrimAge2

Atherogenic Central Load Index

downin humans1

1 study
  1. Atherogenic Central Load Index is associated with IL-6 in humans (r = −0.48 before, r = −0.59 after).

    “Different results were obtained when IL-6 values were correlated with AIP and ACLI values at the two evaluation times, before: IL-6 vs. ACLI, r = −0.48, p < 0.001, B; after: IL-6 vs. ACLI, r = −0.59, p < 0.001, D), compared to the results of the IL-6 vs. AIP correlation (before: IL-6 vs. AIP, r = −0.13”

    Human trial6 monthsn = 73

    Impact of a Hypocaloric Diet on Prognostic Biomarkers of Endothelial Dysfunction: A Prospective Study

    Journal of clinical medicine

  2. Atherogenic Central Load Index is associated with IL-6 in humans (p < 0.05).

    “ACLI showed a strong, inversely significant correlation (p < 0.05) with AIP, hs-CRP and IL-6”

    Human trial6 monthsn = 73

    Impact of a Hypocaloric Diet on Prognostic Biomarkers of Endothelial Dysfunction: A Prospective Study

    Journal of clinical medicine

More on Atherogenic Central Load Index

Dietary inflammatory index

upin humans1

1 study
  1. Dietary inflammatory index is associated with IL-6 in lipedema group.

    “A significant positive correlation was also observed between baseline DII and IL-6 levels in the lipedema group, but not in the overweight/obesity group.”

    Human trialin lipedema group7 months

    Exploring the Anti-Inflammatory Potential of a Mediterranean-Style Ketogenic Diet in Women with Lipedema

    Nutrients

  2. Dietary inflammatory index is associated with IL-6 in humans (lipedema; baseline diet) (r = 0.50).

    “and between the baseline diet's DII and IL-6 (r = 0.50, p = 0.013) in lipedema group.”

    Humanslipedema; baseline dietfemalesn = 24

    Exploring the Anti-Inflammatory Potential of a Mediterranean-Style Ketogenic Diet in Women with Lipedema

    Nutrients

More on Dietary inflammatory index

L-alanine biosynthesis

upin humans1

1 study
  1. L-alanine biosynthesis is associated with IL-6 in humans (overweight women consuming Diet Pepsi) (Spearman rho = 0.74; q < 0.01).

    “L-alanine biosynthesis (PWY0-1061) was positively correlated with circulating IL-6 ({rho} = 0.74; q < 0.01).”

    Human trialoverweight women consuming Diet Pepsi8 weeksfemalesn = 8

    Diet Soda Consumption is Associated with Shifts in Gut Microbiome Function of Overweight Young Women

    medRxivPreprint

MoCA

downin humans1

1 study
  1. IL-6 is associated with MoCA in humans (24 h after surgery) (ρ=-0.419, P<0.001).

    “only IL-6 showed an association with MoCA 24 h after surgery (ρ=-0.419, P<0.001).”

    Human trial24 h after surgery24 hoursn = 60

    Impact of Transurethral Resection of Bladder Cancer in General Anesthesia on Postoperative Cognitive Function, Motor Strength and Biomarker Dynamics

    Preprints.orgPreprint

More on MoCA

All 223

Funding

11 grants since 2016

National Institute on Aging$4.3MNational Institute of Neurological Disorders and Stroke$2.5MUS Department of Veterans Affairs

Contains public sector information licensed under the Open Government Licence v3.0.

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Human studies associate higher IL-6 with mortality and cardiovascular events, link it to cognitive frailty, and report that it predicts immunosenescence. Human trials report decreases with exercise, whole grains, and curcumin, but exercise results also include increases and no change across different populations and protocols.

  2. Summary rewritten as its findings changed.

    As it read before

    Higher IL-6 is associated with mortality in human cohorts; other human studies link IL-6 to chronological age, frailty and PhenoAge. Exercise training trials report decreases in older adults with chronic disease or people with sarcopenia; a trial reports an increase after a treadmill session in untrained adults with type 2 diabetes.

  3. Summary rewritten as its findings changed.

    As it read before

    Human cohorts associate IL-6 with mortality, frailty, cardiovascular events and cognitive impairment. Human exercise trials report decreases, but a trial reports an increase after an hour of treadmill walking in untrained people with type 2 diabetes; nicotinamide riboside leaves plasma IL-6 unchanged in stable COPD.

  4. Summary rewritten as its findings changed.

    As it read before

    Human cohorts associate higher IL-6 with heart failure, cardiovascular events, mortality and frailty. A human exercise trial reduces IL-6 in HFrEF with permanent AF, whereas another increases it in FM patients. SGLT2 inhibitors decrease IL-6 in newly diagnosed type 2 diabetes, whereas a review reports no effect.

  5. Summary rewritten as its findings changed.

    As it read before

    In human cohorts, IL-6 associates with age, mortality, pre-pregnancy obesity, plasma p-Tau217, and higher heart failure risk. Human trials show that high-intensity interval training or fasting combined with a ketogenic diet decreases IL-6, while aquatic exercise has no effect.

Latest

Dec 2025: 123Jan 2026: 171Feb 2026: 145Mar 2026: 170Apr 2026: 71May 2026: 77Jun 2026: 86Jul 2026: 83Aug 2026: 84Sep 2026: 90Oct 2026: 169Nov 2026: 801,349 papers in 12 months
bioRxiv

Alzheimer's model mice fare worse in strength tests at middle age

An experiment in male mice found poorer strength-test performance in middle-aged Alzheimer's model mice than controls, despite preserved muscle size and general motor…An experiment in male mice found poorer strength-test performance in middle-aged Alzheimer's model mice than controls, despite preserved muscle size and general motor performance.

Preprint: mouse studyMechanisms
medRxiv

Loneliness linked to poorer bone health in older men

Loneliness was linked to higher fracture odds in men, with an odds ratio of 2.46, but not women, in a prospective cohort of 2,850 adults.Loneliness was linked to higher fracture odds in men, with an odds ratio of 2.46, but not women, in a prospective cohort of 2,850 adults.

Preprint: cohort · 2,850 peopleBones and joints

See all 5,039 papers on IL-6